High endothelial cell proliferation index and high microvessel density in vascular hotspots suggest an active angiogenic process in human colorectal adenocarcinomas. Angiogenesis G...

por Vermeulen, P. B., Dirix, L. Y., Van Marck, E., Van Oosterom, A. T.
Publicado 1996

A comparison of two culture techniques: an in vitro & an in vivo tumour colony-forming assay.

por Slee, P. H., Willemze, R., van Oosterom, A. T., Lurvink, E., van den Berg, L.
Publicado 1985

A phase II trial with rosiglitazone in liposarcoma patients

por Debrock, G, Vanhentenrijk, V, Sciot, R, Debiec-Rychter, M, Oyen, R, Van Oosterom, A
Publicado 2003

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Geni...

por De Mulder, P. H., Oosterhof, G., Bouffioux, C., van Oosterom, A. T., Vermeylen, K., Sylvester, R.
Publicado 1995

Prognostic value of bcl-2 expression in invasive breast cancer.

por Hellemans, P., van Dam, P. A., Weyler, J., van Oosterom, A. T., Buytaert, P., Van Marck, E.
Publicado 1995

Variations in exposure to mitomycin C in an in vitro colony-forming assay.

por Slee, P. H., de Bruijn, E. A., Leeflang, P., Kuppen, P. J., van den Berg, L., van Oosterom, A. T.
Publicado 1986

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11

por Wildiers, H, Guetens, G, De Boeck, G, Verbeken, E, Landuyt, B, Landuyt, W, de Bruijn, E A, van Oosterom, A T
Publicado 2003

Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.

por Dirix, L. Y., Vermeulen, P. B., Pawinski, A., Prové, A., Benoy, I., De Pooter, C., Martin, M., Van Oosterom, A. T.
Publicado 1997

Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study.

por Vermeulen, P. B., Verhoeven, D., Fierens, H., Hubens, G., Goovaerts, G., Van Marck, E., De Bruijn, E. A., Van Oosterom, A. T., Dirix, L. Y.
Publicado 1995

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.

por Bontenbal, M., Andersson, M., Wildiers, J., Cocconi, G., Jassem, J., Paridaens, R., Rotmensz, N., Sylvester, R., Mouridsen, H. T., Klijn, J. G., van Oosterom, A. T.
Publicado 1998

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.

por Pronk, L. C., Schrijvers, D., Schellens, J. H., de Bruijn, E. A., Planting, A. S., Locci-Tonelli, D., Groult, V., Verweij, J., van Oosterom, A. T.
Publicado 1998

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study

por Fokkema, E, Verweij, J, van Oosterom, A T, Uges, D R A, Spinelli, R, Valota, O, de Vries, E G E, Groen, H J M
Publicado 2000

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

por Punt, C. J., Voest, E. E., Tueni, E., Van Oosterom, A. T., Backx, A., De Mulder, P. H., Hecquet, B., Lucas, C., Gerard, B., Bleiberg, H.
Publicado 1997

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

por Wachters, F M, Groen, H J M, Maring, J G, Gietema, J A, Porro, M, Dumez, H, de Vries, E G E, van Oosterom, A T
Publicado 2004

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)

por Fosså, S D, Paluchowska, B, Horwich, A, Kaiser, G, de Mulder, P H M, Koriakine, O, van Oosterom, A T, de Prijck, L, Collette, L, de Wit, R
Publicado 2005

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

por Huygh, G., Clement, Paul M. J., Dumez, H., Schöffski, P., Wildiers, H., Selleslach, J., Jimeno, J. M., Wever, I. De, Sciot, R., Duck, L., Van Oosterom, A. T.
Publicado 2006

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

por de Wit, R., Collette, L., Sylvester, R., de Mulder, P. H., Sleijfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Stoter, G.
Publicado 1998

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous...

por de Wit, R., Sylvester, R., Tsitsa, C., de Mulder, P. H., Sleyfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Vermeylen, K., Stoter, G.
Publicado 1997

Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

por Bakker, M., Droz, J. P., Hanauske, A. R., Verweij, J., van Oosterom, A. T., Groen, H. J., Pacciarini, M. A., Domenigoni, L., van Weissenbruch, F., Pianezzola, E., de Vries, E. G.
Publicado 1998